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Background and novelty
N-glycans constitute an important information carrier
in protein-driven signaling networks. Amongst others,
N-glycans contribute to protein folding quality, adjust
protein turnover and operate as address label for tar-
geting proteins to specific cells and tissues [1]. Hence,
the composition of N-glycans attached to recombinant
glycoprotein therapeutics is vital for in-vivo therapeutic
efficacy and strongly depends on the choice of the
expression host [2,3]. Due to absence or silencing
of glycosyltransferase genes homologue to human
enzymes, biotechnologically used cell lines are limited
by their intrinsic glycosylation machinery and produce
host specific glycoforms.
Cetuximab, a therapeutic chimeric mouse/human
monoclonal antibody (IgG1), is N-glycosylated both at the
CH2-domain (Asn299) and at the VH-domain (Asn88)
(Figure 1A). Sold under the trade name Erbitux®, Cetuxi-
mab is expressed from a murine myeloma cell line and
targets the human EGF receptor [4], which is overex-
pressed in about 1/3 of all human cancers. The antibody is
highly decorated with the aGal-epitope (Gala1-3Galb1-
4GlcNAc) which has been shown to result in fatal allergic/
hypersensitivity response in several patients [5].
The design of new quality-optimized and functionally
improved biopharmaceuticals with properties conferred
by host cell unrelated N-glycans requires a rational
Golgi engineering strategy. Here, we apply GET, a
system that enables the positioning of a desired catalytic
glycosyltransferase activity into a favorable localization
within the intracellular glycosylation machinery, to sus-
pension CHO cells developed to secrete suitable
amounts (200 μg/ml) of Cetuximab as a model glyco-
protein. The presented Golgi engineering project aims
in the extension of the intrinsic glycosylation repertoire
enabling CHO cells to produce new human-type glyco-
sylation motifs as indicated in Figure 1A: (i) Gal-
NAcb1,4GlcNAc-R (LacdiNAc, LDN),(ii) GlcNAc in
b1,4 linkage to central mannose residue (bisecting
GlcNAc, bGN), (iii) Galb1,4(Fuca1,3)GlcNAc-R (LewisX,
LeX) and (iv) NeuAca2,3Galb1,4 (Fuca1,3)GlcNAc-R
(Sialyl-LewisX, sLeX). To assemble (ii) and (iv), we co-
express GnT3 and FT7. As shown earlier, the latter
enzyme catalyzes fucosylation exclusively of (iv). There-
fore, we included in our study a variant of FT6 that is
targeted to the early Golgi compartment with the aim to
additionally generate structure (iii) [6,7]. The uncom-
mon LDN motif (i) which is e.g. detected on lutropin is
assembled by human B4GalNT3 [8,9]. We analyze oligo-
saccharides released from the products of genetically
engineered CHO cells based on the resolution of single
glycosylation sites of VH- and CH2- glycopeptides by
quantitative NP-HPLC-FLD and use our comprehensive
oligosaccharide standard library to identify novel oligo-
saccharide motifs.
Experimental approach
Cloning of human glycosyltransferases and engineering
of VARFT6 [7] as well as construction of pGET expres-
sion plasmids encoding either the heavy and light chain
of Cetuximab or the glycosyltransferase cDNAs was
done acc. to standard DNA technologies. A stable clone
with Cetuximab titers of 200 μg/ml and doubling times
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of 25 hours was selected after transfection of pGET-
Cetuximab in CHO cells. This clone was either mock-
or co-transfected with pGET plasmids encoding the
indicated glycosyltransferases. After shake flask subculti-
vation for 72 h Cetuximab was purified from superna-
tants, digested and applied to RP-HPLC peptide
mapping. CH2- and VH-domain glycopeptides were
separated and oligosaccharides were enzymatically
released. After 2-AB labeling, the isolated oligosacchar-
ides were subjected to quantitative NP-HPLC-FLD and
ESI-TOF-MS and MS/MS analysis. Oligosaccharide
structures were unambiguously identified in comparison
to GlycoThera’s reference standard oligosaccharide
library.
Results and discussion
n combination with our site specific and quantitative
micro glycan structure analysis we provide a modular
system (GET) for the customized assembly of novel
CHO unrelated oligosaccharide motifs. As exemplified
for VH-domain, the NP-HPLC-FLD elution profiles of
2-AB labeled oligosaccharides after heterologous co-
expression of Cetuximab and the indicated glycosyl-
transferases are shown in Figure 1B. Quantitative
results of all oligosaccharide structures are given in
Figure 2. The Mock-transfected control approach
reveals the intrinsic glycosylation repertoire of our
stable CHO cell clone. Cetuximab is decorated with
agalactosylated (35,5%), mono- (50,0%) and di-galacto-
sylated (10,1%) diantennary complex-type N-glycans
containing proximal a1,6-linked fucose at the CH2-
domain. VH-domain N-glycans consist of neutral
(13,8%), mono- (50,3%) and di-sialylated (35,8%) oligo-
saccharide structures. Whereas N-glycans from the
market product Erbitux® produced in SP2/0 cells are
extensively decorated with Gala1,3Gal and NeuGc
(data not shown), those allergenic structures are not
detected in Cetuximab N-glycans from our CHO cell
clone.
The heterologous co-expression of wildtype
B4GalNT3, GnT3 and FT7 and genetically modified
FT6 results in the formation of the uncommon Lacdi-
NAc motif (ca. 40%), the LewisX and di-LewisX struc-
tures (ca. 50%) and Sialyl-LewisX (ca. 15%) almost
exclusively on oligosaccharides from the VH-domain.
Relevant modification of both VH-domain (ca. 40%) and
CH2-domain glycans (ca. 30%) is only achieved by
GnT3 catalyzed attachment of bisecting GlcNAc. In
addition, glycosyltransferase co-expression leads to
charge state reduction of oligosaccharides by depletion
of suitable acceptors for endogenous sialyltransferases.
The strongest reduction in the content of neuraminic
acid at VH-domain was observed by co-expression of
VARFT6 (ca. 55% reduction) and WTB4GalNT3 (ca. 50%
reduction).
As a conclusion, Golgi engineering endows CHO cells
to assemble significant amounts of LacdiNAc, bisecting
GlcNAc, LewisX and Sialyl-LewisX to Cetuximab N-gly-
cans (Figure 1B and Figure 2). Therefore, our glycosyla-
tion engineering strategy provides a tool to produce
tailored N-glycosylation variants with defined structural
motifs. As demonstrated, the tailored addition of bisect-
ing GlcNAc to CH2-domain N-glycans increases ADCC
of an aCD20 therapeutic mAB [10]. We therefore
assume that the presented structural motifs exhibit
novel therapeutic properties (ADCC, CDC, tissue speci-
ficity, serum half-life). Our strategy represents a relevant
basis for the development of biotherapeutics and biobet-
ters with potentially improved pharmacokinetics, phar-
macodynamics, safety properties and in vivo therapeutic
efficacy.
Figure 1 (A) Non-reducing terminal oligosaccharide motifs
attached to N-glycans of specific human glycoproteins (left side).
Scheme of model glycoprotein Cetuximab with CH2- and VH-
domain N-glycans (right side). (B) NP-HPLC-FLD elution profiles of 2-
AB labeled oligosaccharides from VH-domain of Cetuximab after co-
expression of the indicated glycosyltransferases.
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